linjc16/ctgov huggingface dataset:
Classification of Stanford for Snore as Factor of Aggravation of the Apnea Hypopnea Index (AIH) in Patients With Obstructive Sleep Apnea Syndrome (OSAS)

Study Overview
=================
Brief Summary
-----------------
Introduction: Obstructive sleep apnea syndrome (OSAS) became an important and prevalent illness in recent years. The population occidental becomes fat each time, and this symptom is associated the biggest risk for the OSAS. Snore presence is extremely associated with OSAS. Snoring is present in about 90 - 95% of the patients with OSAS. Objectives: Evaluate the influence in the Stanford classification as predictor factor of gravity of the OSAS. Materials and Methods: They evaluated and classified 107 patients, Classification of Mallampati, Friedman, Classification of Stanford and how much the gravity of the OSAS for the AIH.

Official Title
-----------------
Classification of Stanford for Snore as Factor of Aggravation of the AIH in Patients With OSAS.

Conditions
-----------------
Obstructive Sleep Apnea Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Not exhibiting any exclusion criteria Age > 21 years Exclusion Criteria: Nasal tumor BMI >40 Nasal polipose No acceptance of study

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>OSAS patients | |
| 2<br>no OSAS patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stanford Classification for snoring |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apnea-Hyponea Index |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Classification of Stanford for Snoring, OSAS, Apnea-Hipopnea Index
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Study Overview
=================
Brief Summary
-----------------
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.

Detailed Description
-----------------
The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.

Official Title
-----------------
Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: Infliximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings Exclusion Criteria: •patients who has proven to have infliximab antibody

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TIM-3<br>T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity. | Drug: Infliximab<br> <br> * Other names: Remicade;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy | Disease Activity Index (PCDAI) scores, Peripheral blood for TIM-3 mRNA expression | 1-year treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's disease, Infliximab, T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)
Long-term Treatment With the Ketogenic Diet in Epilepsy

Study Overview
=================
Brief Summary
-----------------
This study will provide a comprehensive assessment of long-term treatment with the ketogenic diet, a medical diet with high fat and low carbohydrate intake, focusing on safety and cardiovascular implications. We will assess patients with epilepsy or one of two rare metabolic diseases; glucose transporter type 1 deficiency syndrome (GLUT1 DS) or pyruvate dehydrogenase complex deficiency (PDHD).

Official Title
-----------------
Long-term Treatment With the Ketogenic Diet in Epilepsy and Epilepsy-related Rare Diseases

Conditions
-----------------
Epilepsy, GLUT1DS1, PDH Deficiency

Intervention / Treatment
-----------------
* Other: Color duplex ultrasound of the carotid arteries


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment with the ketogenic diet at the National Centre for Epilepsy (SSE) for 5 years or more Able to travel from The National Centre for Epilepsy - SSE (Sandvika) to Rikshospitalet (Gaustad) to perform procedures to investigate cardiovascular risk factors Willing to draw extra blood for research purposes Willing to sign informed consent and participate in the study in accordance with the study protocol Willing to sign informed consent for blood samples to be included in research biobank at the Department of Neurology, Oslo University Hospital Exclusion Criteria: Non-compliance with the dietary treatment for 6 months or longer or more than once per month Not possible to communicate with parents in Norwegian or English without interpreter Patient not able to cooperate and lie still for about ten minutes during the carotid ultrasound examination Psychiatric/mental illness, alcohol or drug abuse or other factors making it impossible to pursue the study protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular risk after long-term treatment with the ketogenic diet | Color duplex ultrasound | 2018-2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ketogenic dieting
Measurement of Mandibular Radio Morphometric Indices in Egyptian Population at Different Ages

Study Overview
=================
Brief Summary
-----------------
this study aims to correlate mandibular indices and different ages in a sample of Egyptian population.

Detailed Description
-----------------
this study is an observational cross sectional study to correlate the mandibular radiomorphometric indices with age in sample of egyptian population using CBCT scans at faculty of dentistry cairo university

Official Title
-----------------
Measurement of Mandibular Radio Morphometric Indices in Egyptian Population at Different Ages Using Cone Beam Computed Tomography: A Cross Sectional Study

Conditions
-----------------
Mandibular Fractures

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egyptian individuals with different ages starting from 10 - 70 years. Females and males of the mentioned ages. Exclusion Criteria: Individuals younger than 10 and older than 70 years old. Presence of a large pathological lesions in the mandible at the areas intended for measurements. Patients of severely resorbed mandibular bone. Patients with any bony deformity at the inferior border of the mandible. Patients with fracture at the areas to be examined. Patients with evident radiographic asymmetry. Patients with evident radiographic abnormality suggestive of systemic disease predisposing to osteoporosis. Patients with current postoperative surgical defect healing at the areas intended for measurements. Patients with mandibular reconstruction

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| panoramic mandibular index | ratio between the thickness of the mandible at the mental foramen area and the distance measured from the inferior border of the mental foramen to the inferior border of the mandible. The value of 0.3 will be considered as normal value while the lower value indicate abnormal inferior border thickness | 2018-2020 |
Standardized Dysphagia Diet in Clinical Evaluation of Swallowing Function

Study Overview
=================
Brief Summary
-----------------
Diet modification has been a vital component in the management of dysphagia. The lingual manipulation of bolus, pharyngeal propulsion, and initiation of swallowing reflex are all affected by the texture of bolus. However, there is a limited literature and consensus regarding how to apply different food consistency in the swallowing function evaluation of dysphagic patients. Recently, International Dysphagia Diet Standardization Initiative (IDDSI) has provided a universal standard of food consistency. The present study aims to evaluate the accuracy of clinical swallowing evaluation using IDDSI standardized food in dysphagic patients, in an attempt to establish protocols of clinical evaluation and diet selection in dysphagic patients.

Official Title
-----------------
The Application of Standardized Dysphagia Diet in Clinical Evaluation of Swallowing Function in Dysphagia Patients

Conditions
-----------------
Dysphagia, Swallowing Function, Diet Modification, Dysphagia Diet, Diet Standardization

Intervention / Treatment
-----------------
* Other: FEES


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 20 years or older with a swallowing disorder on the Functional Oral Intake Scale (FOIS) of 1-6. Exclusion Criteria: Unconscious, unable to communicate via gestures or words and cooperate with commands. Acutely infected or requiring respirator use. The oropharyngeal structure is abnormal and cannot be examined by endoscopy. Presence of tracheostomy tube

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Penetration aspiration scale (PAS) | Penetration aspiration scale | Day 1 |
Sensors Prediction Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test whether measures of balance and agility can help predict if a Service Member may be at risk for an injury to their legs before beginning their school and training.

Official Title
-----------------
Body-Worn Sensors for Risk of Injury Prediction During Military Training

Conditions
-----------------
Injury Leg

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 18-55 Active duty Service Members in the 82nd Airborne Division (ABN DIV) Fluent in English speak and reading Exclusion Criteria: Service members under the age of 18 or over the age of 55 will be excluded Told by a doctor that they should not exercise. Orthopedic injury/surgery of the lower limb or back within the last year and that limits study compliance Regular use of medications that may alter balance, coordination or agility Unwilling to comply with the study protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Airborne Group<br>Participants in this group will be tested for balance and agility within a 20 minute time frame. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Region of Limb Stability | Region of Limb Stability (ROLS) measured in cm^2 using a body-worn sensor. | Day 1 | 
| Transitional Angular Displacement of Segments | Transitional Angular Displacement of Segments (TADS) measured in degrees per second using a body-worn sensor. | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip injury, knee injury, ankle injury
Shared Mental Health Care Linking Mental Health Services With Family Medicine Groups

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess how a multidisciplinary team of mental health professionals provides services to patients from two family medicine practices.

Official Title
-----------------
Shared Mental Health Care Linking General Hospital Acute Care Mental Health Services With Two Comprehensive Family Medicine Groups

Conditions
-----------------
Psychosocial Factors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred by family physicians

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psychosocial
A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.

Official Title
-----------------
A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD6280 on Sedation, Cognition and EEG in Comparison With Lorazepam in Healthy Male Volunteers

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: AZD6280
* Drug: AZD6280
* Drug: Lorazepam
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female subjects aged 18 to 55 years (inclusive) on Day 1. Female subjects must be of non-child bearing potential. Exclusion Criteria: Clinically significant illness within 2 weeks before the study start. Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2 Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: AZD6280<br>* 10mg Capsule, oral, single-dose<br>|
| Experimental: 2<br> | Drug: AZD6280<br>* 40mg Capsule, oral, single-dose<br>|
| Active Comparator: 3<br> | Drug: Lorazepam<br>* 2mg tablet, oral single-dose<br>* Other names: Ativan;|
| Placebo Comparator: 4<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the pharmacodynamic effects of AZD6280 by central nervous system function tests |  | Test batteries will be performed at specified times both before and following study drug administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation and characterization of the pharmacokinetics of AZD6280 |  | Blood samples will be taken during the study. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phase I
The Pediatric Anesthesia Quality Improvement Project

Study Overview
=================
Brief Summary
-----------------
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.

Official Title
-----------------
The Pediatric Anesthesia Quality Improvement Project

Conditions
-----------------
Surgery, Anesthesia, Children

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children undergoing anesthesia at participating hospitals Exclusion Criteria: Patients over 21 years of age

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of adverse events |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgery, Children, Anesthesia, Complication
Extending the hCG OPU Interval

Study Overview
=================
Brief Summary
-----------------
Our and others experience suggest that in some cases delaying oocyte pick up (OPU) for more than 39 hours after hCG injection may be of benefit. We plan to apply this to 20 women in whom less than 20% of oocytes were found suitable for intracytoplasmic sperm injection. The delay will be for up to an interval of 47 hours from hCG to OPU.

Detailed Description
-----------------
In IVF one encounters some women in whom a low percentage of oocytes are found in the metaphase II stage upon their retrieval. Following some incidents, in our experience as well as others', where women injected hCG too early but oocytes were still retrieved with high proportion of maturity, we decided to delay OPU intentionally in women who had low percentage oocyte maturity in previous cycles.

Official Title
-----------------
Extending the Time Period Between the Injection of Chorionic Gonadotropin and Oocyte Pick-up as a Solution to Low Rate of Mature Oocyte and Poor Results in Assisted Reproduction

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: Delaying oocyte pick up beyond 39 hours post hCG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous 2 oocyte pick up cycles with 20% metaphase II oocytes in the cohort - Exclusion Criteria: No previous IVF history -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Delay<br>Delaying oocyte pick up beyond 39 hours post hCG | Other: Delaying oocyte pick up beyond 39 hours post hCG<br>* Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Conception |  | Two years |